Carvacrol, a component of thyme oil, activates PPARα and γ and suppresses COX-2 expression

Journal of Lipid Research

Volumn 51, Issue 1, 2010, Pages 132-139

  Hotta, Mariko ^a   Nakata, Rieko ^a   Katsukawa, Michiko ^a   Hori, Kazuyuki ^b   Takahashi, Saori ^b   Inoue, Hiroyasu ^a  

^a NARA WOMEN'S UNIVERSITY   (Japan)

^b Akita Research Institute of Food and Brewing   (Japan)

Author keywords

Cyclooxygenase; Essential oil; Peroxisome proliferator activated receptor; Thymol

Indexed keywords

2 CARENE; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; BERGAMOT OIL; BETA PHELLANDRENE; BORNEOL; CARVACROL; CARYOPHYLLENE; CLOVE OIL; CROTON OIL; CYCLOOXYGENASE 2; EUCALYPTUS OIL; FENNEL OIL; LIMONENE; LINALYL ACETATE; MESSENGER RNA; MYRCENE; PARA CYMENE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PIRINIXIC ACID; ROSE OIL; TERPINENE; TERPINEOL; THYME OIL; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHEMICAL COMPOSITION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REPRESSION; GENE EXPRESSION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE, TUMOR; CYCLOOXYGENASE 2; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; LIPOPOLYSACCHARIDES; MONOTERPENES; OILS, VOLATILE; PLANT OILS; PPAR ALPHA; PPAR GAMMA; PROMOTER REGIONS, GENETIC; THYMUS PLANT;

EID: 73149086389     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M900255-JLR200     Document Type: Article

References (38)

1. Smith, W. L. 2008. Nutritionally essential fatty acids and biologically indispensable cyclooxygenases. Trends Biochem. Sci. 33: 27-33.
2. Simmons, D. L., R. M. Botting, and T. Hla. 2004. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 56: 387-437.
3. Koki, A., N. K. Khan, B. M. Woerner, A. J. Dannenberg, L. Olson, K. Seibert, D. Edwards, M. Hardy, P. Isakson, and J. L. Masferrer. 2002. Cyclooxygenase-2 in human pathological disease. Adv. Exp. Med. Biol. 507: 177-184.
4. Dubois, R. N., S. B. Abramson, L. Crofford, R. A. Gupta, L. S. Simon, L. B. Van De Putte, and P. E. Lipsky. 1998. Cyclooxygenase in biology and disease. FASEB J. 12: 1063-1073.
5. Morham, S. G., R. Langenbach, C. D. Loftin, H. F. Tiano, N. Vouloumanos, J. C. Jennette, J. F. Mahler, K. D. Kluckman, A. Ledford, C. A. Lee, et al. 1995. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell. 83: 473-482.
6. Grosser, T., S. Fries, and G. A. FitzGerald. 2006. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 116: 4-15.
7. Mangelsdorf, D. J., C. Thummel, M. Beato, P. Herrlich, G. Schutz, K. Umesono, B. Blumberg, P. Kastner, M. Mark, and P. Chambon. 1995. The nuclear receptor superfamily: the second decade. Cell. 83: 835-839.
8. Michalik, L., J. Auwerx, J. P. Berger, V. K. Chatterjee, C. K. Glass, F. J. Gonzalez, P. A. Grimaldi, T. Kadowaki, M. A. Lazar, S. O'Rahilly, et al. 2006. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev. 58: 726-741.
9. Sonoda, J., L. Pei, and R. M. Evans. 2008. Nuclear receptors: decoding metabolic disease. FEBS Lett. 582: 2-9.
10. Forman, B. M., P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and R. M. Evans. 1995. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 83: 803-812.
11. Kliewer, S. A., J. M. Lenhard, T. M. Willson, I. Patel, D. C. Morris, and J. M. Lehmann. 1995. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell. 83: 813-819.
12. Inoue, H., T. Tanabe, and K. Umesono. 2000. Feedback control of cyclooxygenase-2 expression through PPARgamma. J. Biol. Chem. 275: 28028-28032.
13. Staels, B., W. Koenig, A. Habib, R. Merval, M. Lebret, I. P. Torra, P. Delerive, A. Fadel, G. Chinetti, J. C. Fruchart, et al. 1998. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature. 393: 790-793.
14. St. Leger, A. S., A. L. Cochrane, and F. Moore. 1979. Factors associated with cardiac mortality in developed countries with particular reference to the consumption of wine. Lancet. 1: 1017-1020.
15. Renaud, S., and M. De Lorgeril. 1992. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet. 339: 1523-1526.
16. Ferrières, J. 2004. The French paradox: lessons for other countries. Heart. 90: 107-111.
17. Subbaramaiah, K., W. J. Chung, P. Michaluart, N. Telang, T. Tanabe, H. Inoue, M. Jang, J. M. Pezzuto, and A. J. Dannenberg. 1998. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem. 273: 21875-21882.
18. Inoue, H., X. Jiang, T. Katayama, S. Osada, K. Umesono, and S. Namura. 2003. Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor alpha in mice. Neurosci. Lett. 352: 203-206.
19. Liang, Y. C., Y. T. Huang, S. H. Tsai, S. Y. Lin-Shiau, C. F. Chen, and J. K. Lin. 1999. Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages. Carcinogenesis. 20: 1945-1952.
20. Woo, K. J., Y. J. Jeong, H. Inoue, J. W. Park, and T. K. Kwon. 2005. Chrysin suppresses lipopolysaccharide-induced cyclooxygenase-2 expression through the inhibition of nuclear factor for IL-6 (NF-IL6) DNA-binding activity. FEBS Lett. 579: 705-711.
21. Yamamoto, K., J. Wang, S. Yamamoto, and H. Tobe. 2000. Suppression of cyclooxygenase-2 gene transcription by humulon of beer hop extract studied with reference to glucocorticoid. FEBS Lett. 465: 103-106.
22. Liang, Y. C., S. H. Tsai, D. C. Tsai, S. Y. Lin-Shiau, and J. K. Lin. 2001. Suppression of inducible cyclooxygenase and nitric oxide synthase through activation of peroxisome proliferator-activated receptor-gamma by flavonoids in mouse macrophages. FEBS Lett. 496: 12-18.
23. Yajima, H., E. Ikeshima, M. Shiraki, T. Kanaya, D. Fujiwara, H. Odai, N. Tsuboyama-Kasaoka, O. Ezaki, S. Oikawa, and K. Kondo. 2004. Isohumulones, bitter acids derived from hops, activate both peroxisome proliferator-activated receptor alpha and gamma and reduce insulin resistance. J. Biol. Chem. 279: 33456-33462.
24. Inoue, H., T. Nanayama, S. Hara, C. Yokoyama, and T. Tanabe. 1994. The cyclic AMP response element plays an essential role in the expression of the human prostaglandin-endoperoxide synthase 2 gene in differentiated U937 monocytic cells. FEBS Lett. 350: 51-54.
25. Inoue, H., Y. Taba, Y. Miwa, C. Yokota, M. Miyagi, and T. Sasaguri. 2002. Transcriptional and posttranscriptional regulation of cyclooxygenase-2 expression by fluid shear stress in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 22: 1415-1420.
26. Inoue, H., and T. Tanabe. 1998. Transcriptional role of the nuclear factor kappa B site in the induction by lipopolysaccharide and suppression by dexamethasone of cyclooxygenase-2 in U937 cells. Biochem. Biophys. Res. Commun. 244: 143-148.
27. Kliewer, S. A., K. Umesono, D. J. Noonan, R. A. Heyman, and R. M. Evans. 1992. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature. 358: 771-774.
28. Inoue, H., C. Yokoyama, S. Hara, Y. Tone, and T. Tanabe. 1995. Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin 6 expression site and cAMP response element. J. Biol. Chem. 270: 24965-24971.
29. Castagna, M., Y. Takai, K. Kaibuchi, K. Sano, U. Kikkawa, and Y. Nishizuka. 1982. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J. Biol. Chem. 257: 7847-7851.
30. Herbert, J. M., J. M. Augereau, J. Gleye, and J. P. Maffrand. 1990. Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem. Biophys. Res. Commun. 172: 993-999.
31. Nishimori, T., H. Inoue, and Y. Hirata. 2004. Involvement of the 3′-untranslated region of cyclooxygenase-2 gene in its post-transcriptional regulation through the glucocorticoid receptor. Life Sci. 74: 2505-2513.
32. Lastra, C. A., and I. Villegas. 2005. Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol. Nutr. Food Res. 49: 405-430.
33. Baur, J. A., and D. A. Sinclair. 2005. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 5: 493-506.
34. Baur, J. A., K. J. Pearson, N. L. Price, H. A. Jamieson, C. Lerin, A. Kalra, V. V. Prabhu, J. S. Allard, G. Lopez-Lluch, K. Lewis, et al. 2006. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 444: 337-342.
35. Lagouge, M., C. Argmann, Z. Gerhart-Hines, H. Meziane, C. Lerin, F. Daussin, N. Messadeq, J. Milne, P. Lambert, P. Elliott, et al. 2006. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 127: 1109-1122.
36. Xu, H., M. Delling, J. C. Jun, and D. E. Clapham. 2006. Oregano, thyme and clove-derived flavors and skin sensitizers activate specific TRP channels. Nat. Neurosci. 9: 628-635.
37. Vogt-Eisele, A. K., K. Weber, M. A. Sherkheli, G. Vielhaber, J. Panten, G. Gisselmann, and H. Hatt. 2007. Monoterpenoid agonists of TRPV3. Br. J. Pharmacol. 151: 530-540.
38. Baser, K. H. 2008. Biological and pharmacological activities of carvacrol and carvacrol bearing essential oils. Curr. Pharm. Des. 14: 3106-3119.